Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227118 · ClinicalTrials.gov registry record · Phase 1
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05227118 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 29 participants.
The verdict
NCT05227118, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
Interventions
- DRUG Placebo
- DRUG Elpipodect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227118
The ClinicalTrials.gov registry entry for NCT05227118 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05227118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05227118 about?
NCT05227118 is a clinical study titled "Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)". The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
What is the current status of trial NCT05227118?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-07-01. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT05227118?
The interventions under investigation include: Placebo (DRUG), Elpipodect (DRUG).
Who is sponsoring clinical trial NCT05227118?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.